Steven Cohen’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-10,364
| Closed | -$300K | – | 4220 |
|
|
2025
Q4 | $300K | Buy |
+10,364
| New | +$197K | ﹤0.01% | 3472 |
|
|
2023
Q4 | – | Sell |
-682
| Closed | -$21.6K | – | 2567 |
|
|
2023
Q3 | $21.6K | Buy |
682
+543
| +391% | +$25.8K | ﹤0.01% | 2282 |
|
|
2023
Q2 | $11.4K | Buy |
+139
| New | +$20.3K | ﹤0.01% | 1890 |
|
|
2022
Q1 | – | Sell |
-32,724
| Closed | -$5.09M | – | 1306 |
|
|
2021
Q4 | $5.09M | Buy |
+32,724
| New | +$6.37M | 0.02% | 663 |
|
|
2021
Q3 | – | Sell |
-1,076
| Closed | -$365K | – | 1165 |
|
|
2021
Q2 | $365K | Sell |
1,076
-40,648
| -97% | -$15.4M | ﹤0.01% | 884 |
|
|
2021
Q1 | $16.9M | Buy |
41,724
+4,844
| +13% | +$2.35M | 0.08% | 299 |
|
|
2020
Q4 | $24.5M | Sell |
36,880
-4,877
| -12% | -$2.71M | 0.12% | 232 |
|
|
2020
Q3 | $19.4M | Buy |
+41,757
| New | +$21.1M | 0.1% | 279 |
|
|
2020
Q1 | – | Sell |
-6,000
| Closed | -$860K | – | 972 |
|
|
2019
Q4 | $860K | Sell |
6,000
-13,800
| -70% | -$1.01M | ﹤0.01% | 729 |
|
|
2019
Q3 | $782K | Sell |
19,800
-6,800
| -26% | -$494K | ﹤0.01% | 727 |
|
|
2019
Q2 | $2.69M | Sell |
26,600
-34,775
| -57% | -$4.1M | 0.01% | 608 |
|
|
2019
Q1 | $8.07M | Buy |
61,375
+39,375
| +179% | +$4.95M | 0.04% | 449 |
|
|
2018
Q4 | $2.24M | Buy |
+22,000
| New | +$3.48M | 0.01% | 700 |
|
|
2018
Q3 | – | Sell |
-5,672
| Closed | -$2.53M | – | 1139 |
|
|
2018
Q2 | $2.53M | Sell |
5,672
-1,128
| -17% | -$495K | 0.01% | 728 |
|
|
2018
Q1 | $2.68M | Buy |
+6,800
| New | +$2.69M | 0.01% | 693 |
|
Other funds holding MRSN
Steven Cohen's MRSN Position: Q1 2026 in Review
Steven Cohen sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 10,364 shares — an estimated $300K sold.
Steven Cohen first reported a position in MRSN in Q1 2018 and held it in 15 quarters. The position peaked at $24.5M in Q4 2020. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- Steven Cohen reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- Steven Cohen sold 10,364 Mersana Therapeutics shares in Q1 2026, an estimated $300K.
- Steven Cohen first reported a position in Mersana Therapeutics in Q1 2018 and held it in 15 quarters.
- Steven Cohen's Mersana Therapeutics position peaked at $24.5M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.